Retatrutide research is examining much more than the number on a scale. Across Phase 2 studies, substudies, post hoc analyses, and newer Phase 3 programs, researchers have reported changes in A1C, liver fat, triglycerides, non-HDL cholesterol, blood pressure, inflammatory markers, urine albumin, and estimated kidney filtration.

Taken together, these findings suggest that the retatrutide research program reaches several connected parts of metabolic biology. They do not prove that one compound has “reset” metabolism, reversed disease, repaired every organ, or delivered long-term protection.

The right way to read the program is endpoint by endpoint. Each measurement answers a different question, comes from a specific population, and carries its own limits.